This is a Phase III, one year study to compare the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity between SCD411 and Eylea in subjects with neovascular age-related macular degeneration. Participants are required to be treatment naïve.
Principal Investigator – Dr Fred Chen
For further information about this study please contact the Clinical Trials Office on (08) 9381 0750 or email clinicalresearch@lei.org.au
EUDRACT Number: 2019-004132-37